x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Mendelspod Podcast

Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who"s who in genomics and genomic medicine. www.mendelspod.com

science & medicine natural sciences

All Episodes

26:03

How Liquid Biopsy Is Becoming Standard of Care with...

Mendelspod Podcast ·

2025/07/23

In this episode of Mendelspod, Theral welcomes Dr. Rita Shaknovich, Chief Medical Officer in Agilent’s Life Sciences and Diagnostics group, for a high-level and deeply insightful look at where liquid biopsy technology stands today.With her background in hematopathology and molecular diagnostics, Rita brings clarity to a field that has long promised transformation—and is now delivering. “It’s not the future anymore. It’s actually here,” she says. Liquid biopsy has moved beyond the buzzword phase and

en

27:48

Tracking GMOs in the Gene Editing Era: Frédéric...

Mendelspod Podcast ·

2025/07/17

In this episode of Mendelspod, Theral speaks with Frédéric Debode, Scientific Director at CRA-W in Wallonia, Belgium, about the evolving landscape of GMO detection in the age of gene editing. From early work in real-time PCR to the latest in next-gen sequencing and target enrichment, Debode has been on the front lines of tracking genetically modified organisms—often when the modifications leave almost no trace.What’s at stake? In Europe, labeling GMOs is not just a policy—it’s the law. Debode

en

35:44

From Discovery to Translation: Bruker's Bold New Play...

Mendelspod Podcast ·

2025/07/10

“We’re going to be rewriting the textbooks on how tissues work.”In this compelling reunion with spatial biology pioneer Joe Beechem and a first-time visit from Oliver Braubach, we explore the rapid evolution of spatial technologies at Bruker, a legacy instrumentation company newly resurgent in the spatial space. Following Bruker’s acquisition of Nanostring and Canopy, the company has emerged as a unifying platform where whole-transcriptome discovery meets translational assay development—under one

en

4:53

Tagomics Wins NHS Grant, Unveils De-Methylation...

Mendelspod Podcast ·

2025/07/01

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comIn this episode of Mendelspod, Theral sits down with Rob Neely, co-founder and CSO at Tagomics, to discuss how his company is fusing genomics, epigenomics, and fragmentomics into a single, assumption-free assay for early cancer detection. The conversation begins with breaking news: Tagomics has just received a new grant from the UK’s Innovation Agency a…

en

4:21

From Paris to the Pentagon: Sophie Peresson Maps...

Mendelspod Podcast ·

2025/06/12

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comIn this premium episode of Mendelspod, we’re joined by one of the few people speaking clearly and globally about biosecurity in the era of synthetic biology and AI: Sophie Peresson.A consultant and leader in responsible innovation, Sophie brings an unusually broad and grounded perspective. With experience spanning international law and governance, she p…

en

4:26

From Mitochondria to Protein Degradation: Mike...

Mendelspod Podcast ·

2025/06/05

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comAs artificial intelligence continues to influence the life sciences, some researchers are questioning not just what it can predict, but what it can explain. On this episode, Mike Kiebish, VP of Platform and Translational Sciences at BPGbio, discusses the company’s “biology-first” approach to drug discovery—one that begins not with models or literature, …

en

31:29

The Grammar of RNA: Gavin Knott on Gene Editing and...

Mendelspod Podcast ·

2025/05/29

In this episode of Mendelspod, we plunge into the shape-shifting world of RNA with Dr. Gavin Knott, associate professor at Monash University and alum of Jennifer Doudna’s lab. Knott is part of a new generation of researchers setting structural biology ablaze with AI, decoding RNA-guided systems and expanding the CRISPR toolbox far beyond its original scope.Knott introduces the listener to RNA not just as code, but as living language. He discusses how AI now allows scientists to see molecules in 3D

en

4:19

The Third Way: Christian Schafmeister’s Spiroligomer...

Mendelspod Podcast ·

2025/05/22

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comFor decades, drug discovery has followed two main roads: small molecules that can slip into cells but often lack precision, and biologics that offer specificity but struggle with delivery and manufacturing. In this episode, Christian Schafmeister introduces us to a third path: spiroligomers—synthetic, fused-ring molecules designed to combine the best of…

en

21:34

Can Math and AI Replace Some Biology in Drug...

Mendelspod Podcast ·

2025/05/15

What if drug design didn’t depend on pre-existing biological data? In this episode of Mendelspod, Theral sits down with Aridni Shah, co-founder and CEO of Immunito AI, a Bengaluru-based biotech startup reinventing how we develop antibody therapies. Shah and her team are using artificial intelligence to design antibodies from scratch, bypassing traditional animal-based and data-heavy methods. “We no longer need to rely on pre-existing data,” she explains. “We’ve gone to the fundamental atomic level

en

4:12

$10 Genome, $8 Coffee: Rethinking the Economics of...

Mendelspod Podcast ·

2025/05/13

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comYes, the Trump economy has been tough on life science tools—but according to today’s guest, the business model was failing us anyway. It’s time to go back to rethinking the basics.Today we’re joined by Stephane Budel, founding partner at DeciBio, one of the leading market research and consulting firms focused on life science tools and precision medicine…

en

4:54

Quantum Scale: A New Era for Single-Cell Analysis...

Mendelspod Podcast ·

2025/05/08

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comOn today’s episode of Mendelspod, Theral sits down with Giovanna Prout, CEO of Scale Biosciences, to explore a how the company is achieving new orders of magnitude of scale in the single cell space."In the past, single cell was one cell per well—maybe 96 cells per experiment," Prout explains. "Now, with our Quantum Scale platform, we can scale from 85,…

en

42:06

Building Intuition at the Nanoscale: Steve McCloskey...

Mendelspod Podcast ·

2025/05/01

What if you could step inside a molecule? On today’s episode of Mendelspod, we talk with Steve McCloskey, founder and CEO of Nanome, the company bringing virtual reality into the world of drug discovery and molecular modeling. A former nanoengineering student at UC San Diego and a self-described futurist, Steve founded Nanome to create what he calls the "ultimate scientific interface"—a way for scientists not just to visualize molecules, but to interact with them naturally in 3D space.* 0:00 The

en

5:03

Beyond the $100 Genome--the Everyday Sequencing...

Mendelspod Podcast ·

2025/04/29

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comWait! What? Sequencing as a service?That was the reaction when Mark Budde first set out to upend a basic ritual in molecular biology—confirmation Sanger sequencing—with his company Plasmidsaurus. You’ve heard it many times: Illumina machines sequence around 80% of the bases in the world. But as Mark points out in today’s interview, it’s not 80% of th…

en

37:50

What Next for LDTs? A Conversation with Sarah Overton...

Mendelspod Podcast ·

2025/04/22

Just weeks before the FDA’s sweeping rule to regulate laboratory-developed tests (LDTs) was set to take effect, a federal court struck it down. What does this mean for the field of precision medicine and for labs themselves? There are have been those on the side of regulation arguing its importance for reimbursement. Yet many, such as the plaintiffs in this case, the ACLA and AMP, have argued that FDA regulation could stifle innovation in a new field and even force labs to shut down. Today we

en

26:46

AI’s Quiet Revolution in the Pharma Supply Chain with...

Mendelspod Podcast ·

2025/04/17

In today’s show, Theral is joined by Chris Petersen, Chief Technology Officer at Scientist.com, a company sometimes called the "Amazon for science"—though with a great deal more complexity. Chris pulls back the curtain on how AI is transforming the research services marketplace and offers a rare look into how AI is already reshaping the infrastructure of pharma and biotech.Calling this the "tinkering phase" of AI, Chris likens the current moment to the early days of the web—when best practices were

en

25:24

We've Been Misclassifying Childhood AML for Years:...

Mendelspod Podcast ·

2025/04/15

In today’s program, we continue our series on disease subtyping with Dr. Jeffery Klco, a pediatric pathologist and researcher at St. Jude Children’s Research Hospital. Dr. Klco joins us to discuss groundbreaking work recently published in Nature Genetics, which redefines the genomic landscape of childhood acute myeloid leukemia (AML).Klco and his team have identified twelve novel molecular subtypes of pediatric AML—some driven by genetic alterations that had long gone undetected by standard

en

40:41

Aaron Viny: A 21-Year Leukemia Survivor on the...

Mendelspod Podcast ·

2025/04/10

Dr. Aaron Viny, oncologist and researcher at Columbia University, begins today’s conversation with a personal milestone—he’s now been leukemia-free for 21 years. This experience gives his work on cancer a powerful human dimension that comes through in his interview with Theral today—not only in his dedication to patient care, but in his boundary-pushing research on the epigenetic roots of cancer.Dr. Viny’s research focuses on the epigenetic architecture of hematologic malignancies, exploring how

en

29:33

Toward Disease Sub-typing with Ben Busby, DNAnexus

Mendelspod Podcast ·

2025/04/03

We’re happy to welcome back Ben Busby, Principal Scientist at DNAnexus, to dive deeper into the evolving world of disease subtyping and multi-omic data sets. Building on our previous conversation with Busby about the genomic data ecosystem, we explore the shift from single-cause disease models to multifaceted approaches that incorporate genomics, proteomics, imaging, and more."We’re no longer in a world where we’re doing genomics or imaging or proteomics," he explains. "These things are all coming

en

37:36

Synthetic Biology Ready for Its ChatGPT Moment: A...

Mendelspod Podcast ·

2025/04/01

John Cumbers, founder of SynBioBeta, joins Theral for our annual look ahead at the field of synthetic biology and the upcoming SynBioBeta 2025 conference, happening May 6–9 in San Jose. It's obviously a big year for AI, and synthetic biology is no exception. As John puts it, “Biology and AI coming together represents a huge opportunity for us to be able to understand biology and then ultimately engineer biology.” This year’s conference features a strong emphasis on AI's role in scaling and

en

24:01

Beyond the Parts List: Chris Mason and Simon...

Mendelspod Podcast ·

2025/03/27

Today Theral is joined by returning guests Chris Mason of Weill Cornell Medicine and Simon Fredriksson, CEO of Pixelgen Technologies, for a deep dive into the emerging field of cell surface proteomics and its power to illuminate both space biology and cancer research.Chris Mason shares new insights from his work on the Space Omics and Medical Atlas (SOMA), the largest collection of astronaut health data to date. His latest findings confirm that space is more than a hostile environment—it’s a

en

515 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事